Elimination of Aerosol Ribavirin Use in Immunocompromised Patients with Metapneumovirus and Parainfluenza Virus Infections

摘要

BackgroundAdministration of ribavirin by aerosol (AR) is often used in attempted treatment of respiratory virus infections in severely immunocompromised patients and was the standard of care at Stanford Health Care (SHC) in the management of metapneumovirus (MPV), parainfluenza virus (PIV), as well as respiratory syncytial virus infections, in hematopoietic stem cell (HCT) and lung transplant (LT) recipients.